The Drugs for Neglected Diseases initiative (DNDi) is a patients’
needs-driven organization committed to the development of new treatments
for neglected diseases. Created in 2003, DNDi has delivered four
improved treatments for malaria, sleeping sickness and visceral
leishmaniasis. A main DNDi challenge is to build a solid R&D
portfolio for neglected diseases and to deliver preclinical candidates
in a timely manner using an original model based on partnership. To
address this challenge DNDi has remodeled its discovery activities from
a project-based academic-bound network to a fully integrated
process-oriented platform in close collaboration with pharmaceutical
companies. This discovery platform relies on dedicated screening
capacity and lead-optimization consortia supported by a pragmatic,
structured and pharmaceutical-focused compound sourcing strategy.
Ioset, J.-R.; Chang, S. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges. Future Medicinal Chemistry (2011) 3 (11) 1361-1371.